Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) and clinical outcomes in patients with end‐stage renal disease
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14262 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Johann Auer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Intensive Care, St Josef Hospital, Braunau, Austria. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Proprotein Convertase 9. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Intensive Care, St Josef Hospital, Braunau, Austria.
- Department of Cardiology and Intensive Care, Kepler University Hospital, Linz, Austria.
- Paracelsus Medical University, Salzburg, Austria.
- Department of Experimental Cardiology, Medical University of Graz, Austria.
ORCID-Profile: Johann Auer
Zitieren
APA
Auer, J., & Auer, L. (2024). Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) and clinical outcomes in patients with end‐stage renal disease. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14262
Vancouver
Auer J, Auer L. Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) and clinical outcomes in patients with end‐stage renal disease. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14262
BibTeX
@article{Auer2024,
author = {Auer, Johann and Auer, Lisa},
title = {Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) and clinical outcomes in patients with end‐stage renal disease},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14262}
}
EUVIMED